Forme galénique: Suspension injectable dépôt agoniste de la GnRH, disponible en formulations américaines de 1, 3 et 4 mois et japonaises de 1 et 3 mois.
Indication thérapeutique: Indiqué pour le cancer de la prostate, l'endométriose, les fibromes utérins, le cancer du sein post-ménopausique et la puberté précoce centrale.
Conditions de stockage: Conserver au réfrigérateur entre 2 et 8 °C, à l'abri de la lumière, conformément aux exigences habituelles de manipulation des dépôts de leuproréline.

Autres informations

Description supplémentaire:

Luphere Depot, a leuprorelin-based generic equivalent to Lupron/Leuplin, has been sold in Korea since January 2005 and is being developed for the US and Japanese markets. Acting as a GnRH agonist, it is indicated for prostate cancer, endometriosis, uterine fibroids, postmenopausal breast cancer, and central precocious puberty, with 1-, 3-, and 4-month US formulations and 1- and 3-month Japan formulations already researched. The sustained-release depot uses PLGA polymer encapsulation, matches the reference product's pharmacodynamic profile, and is produced in a cGMP facility; the company is seeking an overseas partner to handle bioequivalence studies, registration, and commercialization outside Korea.